Press Releases

10.14.2026

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

10.07.2026

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

10.06.2026

Pfizer Declares Fourth-Quarter 2026 Dividend

10.02.2026

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

10.01.2026

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

09.28.2026

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

09.22.2026

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

09.15.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.08.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

08.27.2026

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

08.14.2026

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

08.04.2026

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance